Artelo Biosciences Approves 3-for-1 Reverse Split, Setting 708,258 Shares Outstanding
Artelo Biosciences’ board approved a 3-for-1 reverse stock split that will combine every three common shares into one, resulting in approximately 708,258 shares outstanding. Shares will begin trading on a split-adjusted basis on Nasdaq on March 10, 2026, under a new CUSIP 04301G706.
1. Reverse Split Approval
On February 27, 2026, Artelo Biosciences’ board unanimously approved a 3-for-1 reverse stock split of its common shares. The action is intended to increase the per-share price to improve marketability and liquidity on the Nasdaq Capital Market.
2. Outstanding Shares and Adjustments
Effective at market open on March 10, 2026, every three issued and outstanding shares will convert into one share, resulting in approximately 708,258 shares outstanding under new CUSIP 04301G706. No fractional shares will be issued; shareholders entitled to fractions will receive whole shares, and all outstanding warrants and derivatives will adjust automatically per their terms.